This study is testing two drugs in people having heart surgery, to see whether either can reduce serious complications such as heart attack, stroke or death. Aspirin thins the blood and can reduce these risks but it increases bleeding during surgery. Another drug can reduce bleeding, but it may counteract the benefits of aspirin. The study is being done at more than 20 hospitals in Australia and around the world.
Evaluation Of Long-Term Clinical And Health Service Outcomes Following Coronary Artery Revascularisation In Western Australia: Future Implications
Funder
National Health and Medical Research Council
Funding Amount
$638,412.00
Summary
Heart attacks occur when arteries of the heart become blocked, and current treatment involves unblocking the affected vessel by inserting a stent fed through a leg artery or using bypass surgery. There are different types of stents and whether they offer better outcomes than surgery in the long-term is currently undecided. We will evaluate whether patients who receive stents have better outcomes after 5 years than patients who have surgery, and what the various costs are to the health system.
Y Chromosome Mechanisms In Coronary Artery Disease
Funder
National Health and Medical Research Council
Funding Amount
$369,076.00
Summary
The Y chromosome determines sex in men and until recently was not thought to contribute to heart disease. We previously found a specific type of Y chromosome that does contribute to heart disease. In the current project we plan to find the exact gene and mechanism in the search as a therapeutic target.
A Study Of The Plaque-modifying Actions Of Colchicine In Stable And Unstable Atherosclerosis: From Mouse Models To Clinical Imaging.
Funder
National Health and Medical Research Council
Funding Amount
$1,198,460.00
Summary
Inflammation causes the plaques in arteries that cause heart attacks and strokes. There is major interest in developing drugs that reduce this inflammation for patients with heart disease. We are studying the effects of colchicine, an anti-inflammatory drug used to treat the joint disease, gout, in order to see whether it also prevents the build up of plaques and their progression to heart attacks and strokes.
LoDoCo2 Low Dose Colchicine For Secondary Prevention In Stable Coronary Heart Disease (the LoDoCo2 Trial)
Funder
National Health and Medical Research Council
Funding Amount
$2,399,884.00
Summary
We are conducting clinical trial in several thousand patients to assess the effect of a common, inexpensive and readily available anti-inflammatory drug, colchicine, on heart attack. Colchicine is widely used for treating gout, which is due to inflammation in joints. Since inflammation is an important process makes a cholesterol plaque unstable and can lead to coronary thrombosis and heart attack, we are hypothesising that cholesterol can limit this process.
Identifying The Site/s Of Modification On The Human L-type Ca2+ Channel Protein Isoforms During Oxidative Stress With Reference To Development Of A Therapeutic Target
Funder
National Health and Medical Research Council
Funding Amount
$360,369.00
Summary
A rise in calcium and free radicals in the heart are associated with the development of heart disease. We have good evidence that a protein in the heart muscle known as the L-type calcium channel mediates changes in calcium in response to free radicals. This proposal will identify how the channel function is altered by free radicals so that a therapeutic target can be designed to prevent altered channel function and development of heart disease during increases in free radicals.
Coronary Artery Calcium Score: Use To Guide Management Of Hereditary Coronary Artery Disease (CAUGHT-CAD)
Funder
National Health and Medical Research Council
Funding Amount
$2,762,082.00
Summary
Lifetime risk of coronary artery disease (CAD) is doubled in families with premature CAD. This study will be the first randomized controlled trial of the use of coronary artery calcium scoring (CCS) in relatives of patients with premature CAD, in which treatment will be initiated based on CCS. At three years, the effectiveness of intervention will be assessed on change in plaque volume at CT coronary angiography. The results inform the guidelines regarding evaluation of families with CAD.
Is The Incidence Of Heart Attack Still Decreasing In Australia? Developing More Reliable Methods For Monitoring Trends In Myocardial Infarction And Coronary Heart Disease
Funder
National Health and Medical Research Council
Funding Amount
$762,021.00
Summary
Our study is a collaboration between the University of WA and the Australian Institute of Health and Welfare to investigate population trends in incidence and outcomes of heart disease and its major sub-groups including heart attack, angina and chest pain. Using linked data from WA, we will identify the sub-groups for which trends over time are a realistic estimate of the true population trends. These will be applied to national data to monitor heart disease more accurately in Australia.
TEXTMEDS – TEXT Messages To Improve MEDication Adherence And Secondary Prevention
Funder
National Health and Medical Research Council
Funding Amount
$1,406,875.00
Summary
TEXTMEDS will evaluate a highly innovative strategy to improve cardiovascular disease secondary prevention using cheap and widely available mobile phone technology. TEXTMEDS is a randomised controlled trial of 1400 patients with acute coronary syndrome that will examine the effect of a semi-personalised secondary prevention support program sent via mobile phone text message on the proportion taking appropriate medications for the secondary prevention of cardiovascular disease and on cardiovascul ....TEXTMEDS will evaluate a highly innovative strategy to improve cardiovascular disease secondary prevention using cheap and widely available mobile phone technology. TEXTMEDS is a randomised controlled trial of 1400 patients with acute coronary syndrome that will examine the effect of a semi-personalised secondary prevention support program sent via mobile phone text message on the proportion taking appropriate medications for the secondary prevention of cardiovascular disease and on cardiovascular risk factors levels (e.g. cholesterol).Read moreRead less
The Aboriginal Cardiovascular Omega-3 Randomised Controlled Trial
Funder
National Health and Medical Research Council
Funding Amount
$1,090,119.00
Summary
CVD is the primary contributor to life expectancy differentials between Indigenous and non-Indigenous Australians. Even when cardioprotective therapies are optimally used, residual risk of adverse events is often observed. Testing of additional therapies that improve survival among Indigenous people with CVD is required. Omega 3 fatty acids can improve multiple atherogenic pathways. This trial will assess the impact of Omega 3 in Aboriginal patients with CVD.